Development and validation of cuproptosis-associated prognostic signatures in WHO 2/3 glioma.

Ye, Zhang; Zhang, Shenqi; Cai, Jiayang; Ye, Liguo; Gao, Lun; Wang, Yixuan; Tong, Shiao; Sun, Qian; Wu, Yu; Xiong, Xiaoxing; Chen, Qianxue

Ye, Zhang; Zhang, Shenqi; Cai, Jiayang; Ye, Liguo; Gao, Lun; Wang, Yixuan; Tong, Shiao; Sun, Qian; Wu, Yu; Xiong, Xiaoxing; Chen, Qianxue.

Afiliación

Ye Z; Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Zhang S; Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
Cai J; Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Ye L; Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
Gao L; Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Wang Y; Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
Tong S; Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Sun Q; Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
Wu Y; Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.
Xiong X; Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
Chen Q; Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China.

Front Oncol ; 12: 967159, 2022.

Article en En | MEDLINE | ID: mdl-36059638

Palabras clave

CDKN2A; FDX1; WHO 2/3 glioma; cuproptosis-associated risk signatures; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google